Reuters Allergan said Monday during its first-quarter earnings call that it’s “deep into the process” of its strategic review of the company amid its stock price slipping over the past year. Allergan CEO Brent Saunders outlined five possible approaches the company’s exploring, which include divesting certain businesses. Investors, Saunders said, are frustrated, and some of […]
